Inclusion body myositis: correlation of clinical outcomes with histopathology, electromyography and laboratory findings

Abstract Objective To determine whether histopathological, electromyographic and laboratory markers correlate with clinical measures in inclusion body myositis (IBM). Methods We reviewed our electronic medical records to identify patients with IBM according to European Neuromuscular Center (ENMC) 20...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Rheumatology (Oxford, England) England), 2022-05, Vol.61 (6), p.2504-2511
Hauptverfasser: Pinto, Marcus V, Laughlin, Ruple S, Klein, Christopher J, Mandrekar, Jay, Naddaf, Elie
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2511
container_issue 6
container_start_page 2504
container_title Rheumatology (Oxford, England)
container_volume 61
creator Pinto, Marcus V
Laughlin, Ruple S
Klein, Christopher J
Mandrekar, Jay
Naddaf, Elie
description Abstract Objective To determine whether histopathological, electromyographic and laboratory markers correlate with clinical measures in inclusion body myositis (IBM). Methods We reviewed our electronic medical records to identify patients with IBM according to European Neuromuscular Center (ENMC) 2011 criteria, seen between 2015 and 2020. We only included patients who had a muscle biopsy and needle electromyography (EMG) performed on the same muscle (opposite or same side). We used a detailed grading system [0 (normal) to 4 (severe)] to score histopathological and EMG findings. Clinical severity was assessed by the modified Rankin scale (mRS), muscle strength sum score (SSS), quadriceps strength and severity of dysphagia on swallow evaluation. Serum markers of interest were creatine kinase level and cN-1A antibodies. Results We included 50 IBM patients, with a median age of 69 years; 64% were males. Median disease duration at diagnosis was 51 months. On muscle biopsy, endomysial inflammation mainly correlated with dysphagia, and inversely correlated with mRS. Vacuoles and congophilic inclusions did not correlate with any of the clinical measures. On EMG, the shortness of motor un it potential (MUP) duration correlated with all clinical measures. Myotonic discharges, and not fibrillation potentials, correlated with the severity of inflammation. Serum markers did not have a statistically significant correlation with any of the clinical measures. Conclusions Dysphagia was the main clinical feature of IBM correlating with endomysial inflammation. Otherwise, inclusion body myositis clinical measures had limited correlation with histopathological features in this study. The shortness of MUP duration correlated with all clinical measures.
doi_str_mv 10.1093/rheumatology/keab754
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2580017455</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/rheumatology/keab754</oup_id><sourcerecordid>2580017455</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-11858fcd17645eab5f51b67055096ce286c62cfcdce1c274ef53afb323c9bd473</originalsourceid><addsrcrecordid>eNqNkM1OwzAQhC0EoqXwBgj5yIFSO7bjhBuq-JMqcYFz5Dh2Y3DiYDuq8vaktFQcOe1K--3s7ABwidEtRjlZ-Fr1jYjOuvWw-FSi5IwegSmmaTJHhCTHhz6hE3AWwgdCiGGSnYIJoSnmeU6nYPPSStsH41pYumqAzeCCiSbcQem8V1bE7chpKK1pjRQWuj5K16gANybWsDYhuk7E-sfHDVRWyejdKLP2oqsHKNoKWlE6P1r1A9SmrUy7DufgRAsb1MW-zsD748Pb8nm-en16Wd6v5pJQHucYZyzTssI8pWz8kWmGy5QjxlCeSpVkqUwTOQJSYZlwqjQjQpckITIvK8rJDFzvdDvvvnoVYtGYIJW1olWuD0XCMoQwp4yNKN2h0rsQvNJF500j_FBgVGwjL_5GXuwjH9eu9hf6slHVYek34xFY7ADXd_-T_AawD5cw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2580017455</pqid></control><display><type>article</type><title>Inclusion body myositis: correlation of clinical outcomes with histopathology, electromyography and laboratory findings</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Pinto, Marcus V ; Laughlin, Ruple S ; Klein, Christopher J ; Mandrekar, Jay ; Naddaf, Elie</creator><creatorcontrib>Pinto, Marcus V ; Laughlin, Ruple S ; Klein, Christopher J ; Mandrekar, Jay ; Naddaf, Elie</creatorcontrib><description>Abstract Objective To determine whether histopathological, electromyographic and laboratory markers correlate with clinical measures in inclusion body myositis (IBM). Methods We reviewed our electronic medical records to identify patients with IBM according to European Neuromuscular Center (ENMC) 2011 criteria, seen between 2015 and 2020. We only included patients who had a muscle biopsy and needle electromyography (EMG) performed on the same muscle (opposite or same side). We used a detailed grading system [0 (normal) to 4 (severe)] to score histopathological and EMG findings. Clinical severity was assessed by the modified Rankin scale (mRS), muscle strength sum score (SSS), quadriceps strength and severity of dysphagia on swallow evaluation. Serum markers of interest were creatine kinase level and cN-1A antibodies. Results We included 50 IBM patients, with a median age of 69 years; 64% were males. Median disease duration at diagnosis was 51 months. On muscle biopsy, endomysial inflammation mainly correlated with dysphagia, and inversely correlated with mRS. Vacuoles and congophilic inclusions did not correlate with any of the clinical measures. On EMG, the shortness of motor un it potential (MUP) duration correlated with all clinical measures. Myotonic discharges, and not fibrillation potentials, correlated with the severity of inflammation. Serum markers did not have a statistically significant correlation with any of the clinical measures. Conclusions Dysphagia was the main clinical feature of IBM correlating with endomysial inflammation. Otherwise, inclusion body myositis clinical measures had limited correlation with histopathological features in this study. The shortness of MUP duration correlated with all clinical measures.</description><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/keab754</identifier><identifier>PMID: 34617994</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><ispartof>Rheumatology (Oxford, England), 2022-05, Vol.61 (6), p.2504-2511</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2021</rights><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-11858fcd17645eab5f51b67055096ce286c62cfcdce1c274ef53afb323c9bd473</citedby><cites>FETCH-LOGICAL-c347t-11858fcd17645eab5f51b67055096ce286c62cfcdce1c274ef53afb323c9bd473</cites><orcidid>0000-0001-6212-1236 ; 0000-0002-9890-6657</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1584,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34617994$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pinto, Marcus V</creatorcontrib><creatorcontrib>Laughlin, Ruple S</creatorcontrib><creatorcontrib>Klein, Christopher J</creatorcontrib><creatorcontrib>Mandrekar, Jay</creatorcontrib><creatorcontrib>Naddaf, Elie</creatorcontrib><title>Inclusion body myositis: correlation of clinical outcomes with histopathology, electromyography and laboratory findings</title><title>Rheumatology (Oxford, England)</title><addtitle>Rheumatology (Oxford)</addtitle><description>Abstract Objective To determine whether histopathological, electromyographic and laboratory markers correlate with clinical measures in inclusion body myositis (IBM). Methods We reviewed our electronic medical records to identify patients with IBM according to European Neuromuscular Center (ENMC) 2011 criteria, seen between 2015 and 2020. We only included patients who had a muscle biopsy and needle electromyography (EMG) performed on the same muscle (opposite or same side). We used a detailed grading system [0 (normal) to 4 (severe)] to score histopathological and EMG findings. Clinical severity was assessed by the modified Rankin scale (mRS), muscle strength sum score (SSS), quadriceps strength and severity of dysphagia on swallow evaluation. Serum markers of interest were creatine kinase level and cN-1A antibodies. Results We included 50 IBM patients, with a median age of 69 years; 64% were males. Median disease duration at diagnosis was 51 months. On muscle biopsy, endomysial inflammation mainly correlated with dysphagia, and inversely correlated with mRS. Vacuoles and congophilic inclusions did not correlate with any of the clinical measures. On EMG, the shortness of motor un it potential (MUP) duration correlated with all clinical measures. Myotonic discharges, and not fibrillation potentials, correlated with the severity of inflammation. Serum markers did not have a statistically significant correlation with any of the clinical measures. Conclusions Dysphagia was the main clinical feature of IBM correlating with endomysial inflammation. Otherwise, inclusion body myositis clinical measures had limited correlation with histopathological features in this study. The shortness of MUP duration correlated with all clinical measures.</description><issn>1462-0324</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqNkM1OwzAQhC0EoqXwBgj5yIFSO7bjhBuq-JMqcYFz5Dh2Y3DiYDuq8vaktFQcOe1K--3s7ABwidEtRjlZ-Fr1jYjOuvWw-FSi5IwegSmmaTJHhCTHhz6hE3AWwgdCiGGSnYIJoSnmeU6nYPPSStsH41pYumqAzeCCiSbcQem8V1bE7chpKK1pjRQWuj5K16gANybWsDYhuk7E-sfHDVRWyejdKLP2oqsHKNoKWlE6P1r1A9SmrUy7DufgRAsb1MW-zsD748Pb8nm-en16Wd6v5pJQHucYZyzTssI8pWz8kWmGy5QjxlCeSpVkqUwTOQJSYZlwqjQjQpckITIvK8rJDFzvdDvvvnoVYtGYIJW1olWuD0XCMoQwp4yNKN2h0rsQvNJF500j_FBgVGwjL_5GXuwjH9eu9hf6slHVYek34xFY7ADXd_-T_AawD5cw</recordid><startdate>20220530</startdate><enddate>20220530</enddate><creator>Pinto, Marcus V</creator><creator>Laughlin, Ruple S</creator><creator>Klein, Christopher J</creator><creator>Mandrekar, Jay</creator><creator>Naddaf, Elie</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6212-1236</orcidid><orcidid>https://orcid.org/0000-0002-9890-6657</orcidid></search><sort><creationdate>20220530</creationdate><title>Inclusion body myositis: correlation of clinical outcomes with histopathology, electromyography and laboratory findings</title><author>Pinto, Marcus V ; Laughlin, Ruple S ; Klein, Christopher J ; Mandrekar, Jay ; Naddaf, Elie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-11858fcd17645eab5f51b67055096ce286c62cfcdce1c274ef53afb323c9bd473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pinto, Marcus V</creatorcontrib><creatorcontrib>Laughlin, Ruple S</creatorcontrib><creatorcontrib>Klein, Christopher J</creatorcontrib><creatorcontrib>Mandrekar, Jay</creatorcontrib><creatorcontrib>Naddaf, Elie</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pinto, Marcus V</au><au>Laughlin, Ruple S</au><au>Klein, Christopher J</au><au>Mandrekar, Jay</au><au>Naddaf, Elie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inclusion body myositis: correlation of clinical outcomes with histopathology, electromyography and laboratory findings</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><addtitle>Rheumatology (Oxford)</addtitle><date>2022-05-30</date><risdate>2022</risdate><volume>61</volume><issue>6</issue><spage>2504</spage><epage>2511</epage><pages>2504-2511</pages><issn>1462-0324</issn><eissn>1462-0332</eissn><abstract>Abstract Objective To determine whether histopathological, electromyographic and laboratory markers correlate with clinical measures in inclusion body myositis (IBM). Methods We reviewed our electronic medical records to identify patients with IBM according to European Neuromuscular Center (ENMC) 2011 criteria, seen between 2015 and 2020. We only included patients who had a muscle biopsy and needle electromyography (EMG) performed on the same muscle (opposite or same side). We used a detailed grading system [0 (normal) to 4 (severe)] to score histopathological and EMG findings. Clinical severity was assessed by the modified Rankin scale (mRS), muscle strength sum score (SSS), quadriceps strength and severity of dysphagia on swallow evaluation. Serum markers of interest were creatine kinase level and cN-1A antibodies. Results We included 50 IBM patients, with a median age of 69 years; 64% were males. Median disease duration at diagnosis was 51 months. On muscle biopsy, endomysial inflammation mainly correlated with dysphagia, and inversely correlated with mRS. Vacuoles and congophilic inclusions did not correlate with any of the clinical measures. On EMG, the shortness of motor un it potential (MUP) duration correlated with all clinical measures. Myotonic discharges, and not fibrillation potentials, correlated with the severity of inflammation. Serum markers did not have a statistically significant correlation with any of the clinical measures. Conclusions Dysphagia was the main clinical feature of IBM correlating with endomysial inflammation. Otherwise, inclusion body myositis clinical measures had limited correlation with histopathological features in this study. The shortness of MUP duration correlated with all clinical measures.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>34617994</pmid><doi>10.1093/rheumatology/keab754</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-6212-1236</orcidid><orcidid>https://orcid.org/0000-0002-9890-6657</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1462-0324
ispartof Rheumatology (Oxford, England), 2022-05, Vol.61 (6), p.2504-2511
issn 1462-0324
1462-0332
language eng
recordid cdi_proquest_miscellaneous_2580017455
source Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection
title Inclusion body myositis: correlation of clinical outcomes with histopathology, electromyography and laboratory findings
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T08%3A10%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inclusion%20body%20myositis:%20correlation%20of%20clinical%20outcomes%20with%20histopathology,%20electromyography%20and%20laboratory%20findings&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=Pinto,%20Marcus%20V&rft.date=2022-05-30&rft.volume=61&rft.issue=6&rft.spage=2504&rft.epage=2511&rft.pages=2504-2511&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/keab754&rft_dat=%3Cproquest_cross%3E2580017455%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2580017455&rft_id=info:pmid/34617994&rft_oup_id=10.1093/rheumatology/keab754&rfr_iscdi=true